Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 4 | 1 |
List of Figures | 5 | 1 |
Introduction | 6 | 1 |
Global Markets Direct Report Coverage | 6 | 1 |
Dementia Associated With Alzheimer's Disease Overview | 7 | 1 |
Therapeutics Development | 8 | 2 |
Pipeline Products for Dementia Associated With Alzheimer's Disease Overview | 8 | 1 |
Pipeline Products for Dementia Associated With Alzheimer's Disease Comparative Analysis | 9 | 1 |
Dementia Associated With Alzheimer's Disease Therapeutics under Development by Companies | 10 | 1 |
Dementia Associated With Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
Dementia Associated With Alzheimer's Disease Pipeline Products Glance | 12 | 3 |
Clinical Stage Products | 12 | 1 |
Early Stage Products | 13 | 1 |
Unknown Stage Products | 14 | 1 |
Dementia Associated With Alzheimer's Disease Products under Development by Companies | 15 | 1 |
Dementia Associated With Alzheimer's Disease Products under Investigation by Universities/Institutes | 16 | 1 |
Dementia Associated With Alzheimer's Disease Companies Involved in Therapeutics Development | 17 | 8 |
Adamas Pharmaceuticals, Inc. | 17 | 1 |
AgeneBio Inc. | 18 | 1 |
Amarantus Bioscience Holdings, Inc. | 19 | 1 |
Boehringer Ingelheim GmbH | 20 | 1 |
Chase Pharmaceuticals Corporation | 21 | 1 |
Eisai Co., Ltd. | 22 | 1 |
H. Lundbeck A/S | 23 | 1 |
MediPost Co., Ltd. | 24 | 1 |
Dementia Associated With Alzheimer's Disease Therapeutics Assessment | 25 | 10 |
Assessment by Monotherapy Products | 25 | 1 |
Assessment by Combination Products | 26 | 1 |
Assessment by Target | 27 | 2 |
Assessment by Mechanism of Action | 29 | 2 |
Assessment by Route of Administration | 31 | 2 |
Assessment by Molecule Type | 33 | 2 |
Drug Profiles | 35 | 24 |
(donepezil hydrochloride + memantine hydrochloride ER) Drug Profile | 35 | 2 |
(donepezil hydrochloride + solifenacin succinate) Drug Profile | 37 | 2 |
BI-409306 Drug Profile | 39 | 2 |
E-2609 Drug Profile | 41 | 3 |
eltoprazine Drug Profile | 44 | 5 |
Gln-1062 Drug Profile | 49 | 3 |
levetiracetam Drug Profile | 52 | 2 |
LUAF-20513 Drug Profile | 54 | 1 |
Neurostem Drug Profile | 55 | 2 |
salicylamine Drug Profile | 57 | 1 |
TAK-070 Drug Profile | 58 | 1 |
Dementia Associated With Alzheimer's Disease Dormant Projects | 59 | 1 |
Dementia Associated With Alzheimer's Disease Discontinued Products | 60 | 1 |
Dementia Associated With Alzheimer's Disease Product Development Milestones | 61 | 11 |
Featured News &Press Releases | 61 | 1 |
Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation | 61 | 1 |
Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer s Association International Conference | 61 | 2 |
Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering &Investment Forum | 63 | 1 |
Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website | 63 | 1 |
Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression | 64 | 2 |
Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference | 66 | 1 |
Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer s Disease | 67 | 1 |
Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia | 67 | 1 |
Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer s Dementia | 68 | 1 |
Jan 28, 2015: AgeneBio Receives Grant from Alzheimer s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer s Dementia | 69 | 1 |
May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories | 70 | 1 |
May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda | 70 | 2 |
Appendix | 72 | 2 |
Methodology | 72 | 1 |
Coverage | 72 | 1 |
Secondary Research | 72 | 1 |
Primary Research | 72 | 1 |
Expert Panel Validation | 72 | 1 |
Contact Us | 72 | 1 |
Disclaimer | 73 | 1 |